Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. - Wikidata - awgldk - TriplyDB

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.

http://www.wikidata.org/entity/Q34104112

about

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Ibrutinib-A double-edge sword in cancer and autoimmune disorders.Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.Targeting mTOR for the treatment of B cell malignancies.Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options.Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patien A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib.Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity A multiprotein supercomplex controlling oncogenic signalling in lymphoma

P2860

Q27304386-B22D0C6F-6B96-4E84-8997-2FF906DC4655 Q34042250-74A506F2-E02B-493F-8785-A1EF1BD650A6 Q34654655-5DCDDDB5-9B18-4F46-A8B6-0C338464A64D Q35273689-D505F592-5815-4C5B-8EDB-24D3EE84ECFE Q35770299-28D8C921-4F33-49E1-9227-26DA92505EAE Q35979385-C7A4BBE1-BFFF-4E5F-8BF9-4B581E0DF982 Q36546300-E71948FC-4B51-4BE7-8F69-BF8CA17B8637 Q38262117-6D871A94-3030-437C-998D-BC2C82D7E859 Q38311898-C520C1D4-0996-482C-ABBF-B535AC1FDCF7 Q38351184-3382A438-C7EF-4787-95A8-70CA19DFBD98 Q38521775-044F6018-9CCB-477D-90AA-E890087563C1 Q38585329-E16A39CD-68A9-4610-8C39-82B741E9E613 Q38707684-00651797-1156-44D6-A830-737AAB3CABA0 Q38709825-95884DFB-A2FD-4E7D-A53D-C44360268439 Q38720593-2302465E-2CC9-42CD-A0F9-212ADF9EEAAF Q38798340-2F5D09DE-006C-4F4D-B18C-780EC78E3A85 Q38919666-1A23CDFE-BEDA-40A4-8583-768B132F9969 Q38955246-F23CE0F7-90C4-4B76-9299-A186A0A83E44 Q45594363-1624FB2D-F0E9-4DE4-9B2C-02C4DBA470DE Q47804413-303FB71A-BA77-413A-9B8A-E4C522DF543C Q47875518-AFF91F7C-9E7E-4527-9A4B-EDA2746B890A Q49959959-EB8268D9-D474-4EB5-B283-356F96BB8488 Q54112410-CBC11BF4-83C0-439A-8414-011A323C1416 Q56892381-EB5743B4-1169-48DF-9FCE-840B8535AD3D Q57759535-77BEF400-91F5-49CF-923D-E2FE0122FFF7

P2860

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.

http://www.wikidata.org/entity/Q34104112

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@ast

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@en

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@nl

type

label

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@ast

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@en

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@nl

prefLabel

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@ast

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@en

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@nl

P1433

Q34104112-C0D34B84-EA76-443B-B73C-160F77B892A2

P1476

Q34104112-7C82758B-9F2B-469C-9E8E-EBAB34E7406F

P2093

Q34104112-0BFCC22E-604D-4F6D-88E9-9E8890D0CF04

Q34104112-34013683-4D6C-4CE9-9C6D-591BA965B71A

Q34104112-44DCEE56-6956-4B34-9A7A-979606BC6847

Q34104112-4F7AD5F4-5293-422D-9333-A122F0E1B749

Q34104112-9EFD0905-5955-4370-B330-52855CDB6F76

Q34104112-B70D63BF-964F-4DE4-9375-43BBC5B14147

Q34104112-B7DDB82F-140F-4252-BC80-1B1B0F711F51

Q34104112-D78CB327-43D8-4392-A4F7-BC9B6735EB17

Q34104112-E1AA20AD-372E-4923-9ACC-7B0A565E76B9

Q34104112-F4900FCD-4247-4CAF-B9AC-6A07DE5E5CC9

P2860

Q34104112-008E7C67-E903-4FF2-AE2A-C9F9AEB54BAD

Q34104112-147D9A1A-CBA3-462D-B3B8-B293C23FF6CB

Q34104112-15F35FD9-8D08-4709-80C3-846B99605F43

Q34104112-16AF1DEC-B8F7-4E8E-A741-28D44FB41055

Q34104112-1C049519-E5E0-4033-98F9-ED3E53A27812

Q34104112-1F677923-29F2-44B8-A69C-18362D05AF04

Q34104112-26883EBC-FC21-4FCF-9847-2073AD2BF442

Q34104112-2AE3A0D2-3212-4128-AA39-08311FFEAE14

Q34104112-30B4EB29-9C5A-41E1-A792-E2CA5D156D0E

Q34104112-3828DC94-9620-4D54-8262-38EFFE22337F

P304

Q34104112-8D49B4D1-4AE9-4387-AD78-FF8E838E5C79

P31

Q34104112-3468D64C-CD01-477D-B263-2E9E69289A20

P356

Q34104112-FEB9E811-336C-4E37-8C0C-AB0DF04757AD

P407

Q34104112-EF3B7CEB-34C9-4ED0-89FB-D513AB44875F

P433

Q34104112-EFD0D3EB-2DC8-41EA-A7B6-1794CE36FC8F

P478

Q34104112-79183DB0-6EFF-4137-A89C-08CA65799A45

P50

Q34104112-7AE94500-32EE-4D0F-B865-DF85AF813885

P577

Q34104112-09E2E49C-41B4-4FD4-A5BF-F154297D0B87

P5875

Q34104112-88234085-F62E-4953-A4B1-C795BD287E26

P698

Q34104112-F544A5EA-BDF2-4D88-AE50-3CDB27713115

P932

Q34104112-32234531-7422-46D4-84B5-CB564FBD1F9F

P356

ONCOTARGET.2071

P1433

P1476

Synergistic induction of apopt ...... diffuse large B cell lymphoma.

@en

P2093

Corinne Reimer

http://www.w3.org/2001/XMLSchema#string

Julie Parmentier

http://www.w3.org/2001/XMLSchema#string

Kate F Byth

http://www.w3.org/2001/XMLSchema#string

Melissa Passino

http://www.w3.org/2001/XMLSchema#string

Michele Mayo

http://www.w3.org/2001/XMLSchema#string

Scott A Ezell

http://www.w3.org/2001/XMLSchema#string

Shaun E Grosskurth

http://www.w3.org/2001/XMLSchema#string

Suping Wang

http://www.w3.org/2001/XMLSchema#string

Suprawee Tepsuporn

http://www.w3.org/2001/XMLSchema#string

Teeru Bihani

http://www.w3.org/2001/XMLSchema#string

P2860

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in response to UVB irradiation

TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production

Oncogenically active MYD88 mutations in human lymphoma

Hierarchical phosphorylation of the translation inhibitor 4E-BP1

Activation of interleukin-6 gene expression through the NF-kappa B transcription factor

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.

Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.

Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.

P304

4990-5001

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2071

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Michael Collins

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263475806

http://www.w3.org/2001/XMLSchema#string

P698

24970801

http://www.w3.org/2001/XMLSchema#string

P932

4148116

http://www.w3.org/2001/XMLSchema#string